F6Publishing

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Articles Published Processes

Keyword: Semaglutide

Page 1 of 1 ( 19 items )
<<
1
>>

1	Semaglutide in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis 3/23/2026 8:54:21 AM \| Browse: 73 \| Download: 344
2	Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy 2/6/2026 8:43:33 AM \| Browse: 106 \| Download: 701
3	Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease 12/23/2025 8:03:21 AM \| Browse: 139 \| Download: 442
4	Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice 10/27/2025 10:57:49 AM \| Browse: 311 \| Download: 674
5	Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation 7/22/2025 8:44:58 AM \| Browse: 263 \| Download: 891
6	Finerenone and semaglutide: Role in heart failure with reduced ejection fraction 5/23/2025 9:07:55 AM \| Browse: 330 \| Download: 659
7	GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis 11/29/2024 8:40:08 AM \| Browse: 287 \| Download: 679
8	Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction–associated steatotic liver disease 8/9/2024 12:51:13 PM \| Browse: 416 \| Download: 976
9	Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications 7/11/2024 8:47:17 AM \| Browse: 381 \| Download: 864
10	Semaglutide for the management of diabesity: The real-world experience 6/25/2024 9:25:52 AM \| Browse: 432 \| Download: 1309
11	Impact of glucagon-like peptide receptor agonists on endoscopy and its preoperative management: Guidelines, challenges, and future directions 6/14/2024 9:22:25 AM \| Browse: 169 \| Download: 790
12	Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon 2/4/2024 10:57:41 AM \| Browse: 364 \| Download: 1261
13	Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1 12/27/2023 5:42:53 AM \| Browse: 513 \| Download: 1614
14	Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis 12/19/2023 2:09:20 AM \| Browse: 787 \| Download: 1468
15	Efficacy and safety of semaglutide in non-alcoholic fatty liver disease 9/25/2023 9:07:43 AM \| Browse: 486 \| Download: 1695
16	Semaglutide-eye-catching results 4/12/2023 11:34:59 AM \| Browse: 434 \| Download: 1339
17	Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? 7/5/2022 1:22:29 AM \| Browse: 626 \| Download: 1572
18	Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy? 9/11/2020 7:11:20 AM \| Browse: 860 \| Download: 1826
19	Effects of glycaemic management on diabetic kidney disease 5/15/2017 10:13:33 AM \| Browse: 1749 \| Download: 2257

Page 1 of 1 ( 19 items )
<<
1
>>

Write to the Help Desk

Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.